Name LATUDA® (Lurasidone)
Description LATUDA® is a once-daily oral atypical antipsychotic. In addition to its well-demonstrated efficacy, LATUDA® with its favorable metabolic safety profile may be a solution for unmet medical needs of schizophrenia patients treated with current antipsychotics.
Indication LATUDA® is indicated for the treatment of schizophrenia in adults aged 18 years and over.

18.5 mg, 37 mg and 74 mg film coated tablets

Regulatory Status

FDA approved in October 2010

EMA approved in March 2014

Latuda® tablets are registered in UAE and KSA.

Business Partner

Sunovion Pharmaceuticals